Hier wird der AstraZeneca-Impfstoff produziert
  • Im Wockhardt-Werk in Wrexham wird der Corona-Impfstoff von AstraZeneca abgepackt.
    1 /9 Im Wockhardt-Werk in Wrexham können pro Jahr 300 Millionen Dosen des Corona-Impfstoffs von AstraZeneca produziert werden.
    ...
    Christopher Thomond / Eyevine / picturedesk.com
  • Download von www.picturedesk.com am 27.01.2021 (15:25). A view of the Wockhardt coronavirus vaccine facility after large parts of central and northern England and Wales were caught in the path of Storm Christoph, in Wrexham, Wales, Thursday Jan. 21, 2021. According to reports teams worked through the night to deal with the effects of Storm Christoph to protect the pharmaceutical manufacturing facility from flooding. (AP Photo Jon Super) - 20210121_PD7593 - Rechteinfo: Rights Managed (RM)
    2 /9 Im Wockhardt-Werk in Wrexham können pro Jahr 300 Millionen Dosen des Corona-Impfstoffs von AstraZeneca produziert werden.
    ...
    Jon Super / AP / picturedesk.com
  • Download von www.picturedesk.com am 27.01.2021 (15:25). Inside Oxford’s coronavirus vaccine development Fill finish of the Oxford AstraZeneca Covid-19 coronavirus vaccine (ChAdOx1 nCoV-19), at Wockhardt in Wrexham, one of the largest generic pharmaceutical companies in the UK. Here the vaccine that was manufactured at Oxford Biomedica and developed by the Oxford Vaccine group is transferred into vials before being packaged ready for distribution. .© David Levene / Guardian / eyevine :...http://. - 20201214_PD10597 - Rechteinfo: Rights Managed (RM)
    3 /9 Im Wockhardt-Werk in Wrexham können pro Jahr 300 Millionen Dosen des Corona-Impfstoffs von AstraZeneca produziert werden.
    ...
    David Levene / Eyevine / picturedesk.com
  • Download von www.picturedesk.com am 27.01.2021 (15:25). Inside Oxford’s coronavirus vaccine development Oxford Biomedica is manufacturing tens of millions of doses of the vaccine on behalf on AstraZeneca. Production involves various stages, starting with a vial of a frozen master bank of cells, which are thawed out and transferred into larger and larger solutions of media, each time being given time to grow. This takes several weeks until eventually there is enough vaccine to fill a 1,000-litre bioreactor. The solution then goes through a process of separation, purification and concentration before being frozen into 15-litre bags which are stored in special trays, ready to be transferred into individual dose vials at a fill/finish house at a different location.Fill finish of the Oxford AstraZeneca Covid-19 coronavirus vaccine (ChAdOx1 nCoV-19), at Wockhardt in Wrexham, one of the largest generic pharmaceutical companies in the UK. Here the vaccine that was manufactured at Oxford Biomedica and developed by the Oxford Vaccine group is transferred into vials before being packaged ready for distribution. .© David Levene / Guardian / eyevine :...http://. - 20201214_PD10595 - Rechteinfo: Rights Managed (RM)
    4 /9 Im Wockhardt-Werk in Wrexham können pro Jahr 300 Millionen Dosen des Corona-Impfstoffs von AstraZeneca produziert werden.
    ...
    David Levene / Eyevine / picturedesk.com
  • Download von www.picturedesk.com am 27.01.2021 (15:25). Inside Oxford’s coronavirus vaccine development Oxford Biomedica is manufacturing tens of millions of doses of the vaccine on behalf on AstraZeneca. Production involves various stages, starting with a vial of a frozen master bank of cells, which are thawed out and transferred into larger and larger solutions of media, each time being given time to grow. This takes several weeks until eventually there is enough vaccine to fill a 1,000-litre bioreactor. The solution then goes through a process of separation, purification and concentration before being frozen into 15-litre bags which are stored in special trays, ready to be transferred into individual dose vials at a fill/finish house at a different location.Fill finish of the Oxford AstraZeneca Covid-19 coronavirus vaccine (ChAdOx1 nCoV-19), at Wockhardt in Wrexham, one of the largest generic pharmaceutical companies in the UK. Here the vaccine that was manufactured at Oxford Biomedica and developed by the Oxford Vaccine group is transferred into vials before being packaged ready for distribution. .© David Levene / Guardian / eyevine :...http://. - 20201214_PD10594 - Rechteinfo: Rights Managed (RM)
    5 /9 Im Wockhardt-Werk in Wrexham können pro Jahr 300 Millionen Dosen des Corona-Impfstoffs von AstraZeneca produziert werden.
    ...
    David Levene / Eyevine / picturedesk.com
  • Download von www.picturedesk.com am 27.01.2021 (15:25). Inside Oxford’s coronavirus vaccine development Fill finish of the Oxford AstraZeneca Covid-19 coronavirus vaccine (ChAdOx1 nCoV-19), at Wockhardt in Wrexham, one of the largest generic pharmaceutical companies in the UK. Here the vaccine that was manufactured at Oxford Biomedica and developed by the Oxford Vaccine group is transferred into vials before being packaged ready for distribution. .© David Levene / Guardian / eyevine :...http://. - 20201214_PD10593 - Rechteinfo: Rights Managed (RM)
    6 /9 Im Wockhardt-Werk in Wrexham können pro Jahr 300 Millionen Dosen des Corona-Impfstoffs von AstraZeneca produziert werden.
    ...
    David Levene / Eyevine / picturedesk.com
  • Download von www.picturedesk.com am 27.01.2021 (15:25). Inside Oxford’s coronavirus vaccine development Oxford Biomedica is manufacturing tens of millions of doses of the vaccine on behalf on AstraZeneca. Production involves various stages, starting with a vial of a frozen master bank of cells, which are thawed out and transferred into larger and larger solutions of media, each time being given time to grow. This takes several weeks until eventually there is enough vaccine to fill a 1,000-litre bioreactor. The solution then goes through a process of separation, purification and concentration before being frozen into 15-litre bags which are stored in special trays, ready to be transferred into individual dose vials at a fill/finish house at a different location.Fill finish of the Oxford AstraZeneca Covid-19 coronavirus vaccine (ChAdOx1 nCoV-19), at Wockhardt in Wrexham, one of the largest generic pharmaceutical companies in the UK. Here the vaccine that was manufactured at Oxford Biomedica and developed by the Oxford Vaccine group is transferred into vials before being packaged ready for distribution. .© David Levene / Guardian / eyevine :...http://. - 20201214_PD10580 - Rechteinfo: Rights Managed (RM)
    7 /9 Im Wockhardt-Werk in Wrexham können pro Jahr 300 Millionen Dosen des Corona-Impfstoffs von AstraZeneca produziert werden.
    ...
    David Levene / Eyevine / picturedesk.com
  • Download von www.picturedesk.com am 27.01.2021 (15:25). Inside Oxford’s coronavirus vaccine development Oxford Biomedica is manufacturing tens of millions of doses of the vaccine on behalf on AstraZeneca. Production involves various stages, starting with a vial of a frozen master bank of cells, which are thawed out and transferred into larger and larger solutions of media, each time being given time to grow. This takes several weeks until eventually there is enough vaccine to fill a 1,000-litre bioreactor. The solution then goes through a process of separation, purification and concentration before being frozen into 15-litre bags which are stored in special trays, ready to be transferred into individual dose vials at a fill/finish house at a different location.Fill finish of the Oxford AstraZeneca Covid-19 coronavirus vaccine (ChAdOx1 nCoV-19), at Wockhardt in Wrexham, one of the largest generic pharmaceutical companies in the UK. Here the vaccine that was manufactured at Oxford Biomedica and developed by the Oxford Vaccine group is transferred into vials before being packaged ready for distribution. .© David Levene / Guardian / eyevine :...http://. - 20201214_PD10588 - Rechteinfo: Rights Managed (RM)
    8 /9 Im Wockhardt-Werk in Wrexham können pro Jahr 300 Millionen Dosen des Corona-Impfstoffs von AstraZeneca produziert werden.
    ...
    David Levene / Eyevine / picturedesk.com
  • Download von www.picturedesk.com am 27.01.2021 (15:26). Inside Oxford’s coronavirus vaccine development Oxford Biomedica is manufacturing tens of millions of doses of the vaccine on behalf on AstraZeneca. Production involves various stages, starting with a vial of a frozen master bank of cells, which are thawed out and transferred into larger and larger solutions of media, each time being given time to grow. This takes several weeks until eventually there is enough vaccine to fill a 1,000-litre bioreactor. The solution then goes through a process of separation, purification and concentration before being frozen into 15-litre bags which are stored in special trays, ready to be transferred into individual dose vials at a fill/finish house at a different location.Fill finish of the Oxford AstraZeneca Covid-19 coronavirus vaccine (ChAdOx1 nCoV-19), at Wockhardt in Wrexham, one of the largest generic pharmaceutical companies in the UK. Here the vaccine that was manufactured at Oxford Biomedica and developed by the Oxford Vaccine group is transferred into vials before being packaged ready for distribution. .© David Levene / Guardian / eyevine :...http://. - 20201214_PD10545 - Rechteinfo: Rights Managed (RM)
    9 /9 Im Wockhardt-Werk in Wrexham können pro Jahr 300 Millionen Dosen des Corona-Impfstoffs von AstraZeneca produziert werden.
    ...
    David Levene / Eyevine / picturedesk.com
Zur Startseite
Jetzt E-Paper lesen